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S U M M A R Y
Background: There are few predictors of the virological response in patients who are re-treated with
antiviral therapies. In this study, we evaluated the levels of chemokines that bind to C-C chemokine
receptor type 5 (CCR5) and their impact on combination therapy in both treatment-naı¨ve and treatment-
experienced patients chronically infected with hepatitis C virus (HCV).
Methods: Longitudinal analysis of CCR5 chemokines was performed using the multiplex Bio-Rad 27-plex
assay in 56 treatment-naı¨ve and 24 treatment-experienced patients with chronic HCV infection during
combination therapy with peginterferon alfa and ribavirin. A group of healthy donors was included as
the control (n = 11).
Results: The pretreatment level of macrophage inﬂammatory protein 1 (MIP-1) was determined to be an
independent predictor, with an ideal predictive threshold for sustained virological response of 95.23 pg/
ml. A rapid decline in HCV RNA was observed in patients with a pretreatment MIP-1 level of <95.23 pg/
ml, while a slow reduction was measured in patients with levels of 95.23 pg/ml (p = 0.014). Of note, the
dynamics of MIP-1 further indicated that a lower level at baseline and at treatment week 12 was
signiﬁcantly associated with a favorable outcome of antiviral therapy (p = 0.014), especially in
treatment-experienced patients (p = 0.04), while a higher level of MIP-1beta correlated with the
elevation of transaminases.
Conclusions: Serum MIP-1 is an independent and effective predictor of early and sustained virological
response in chronically HCV-infected patients undergoing re-treatment.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hepatitis C virus (HCV) is a major cause of chronic liver disease
and infects approximately 170 million people worldwide.1,2 Upon
HCV infection, 70–85% of individuals do not spontaneously resolve
acute HCV infection, resulting in chronic infection with the
potential to develop cirrhosis, end-stage liver disease, and
hepatocellular carcinoma.3 Combination therapy with peginter-
feron alfa and ribavirin is currently the recommended antiviral
therapy for chronic HCV-infected patients, leading to long-term
resolution of infection in only 45–80% of individuals depending on* Corresponding authors. Tel.: +86 133 01030203; fax: +86 10 63054847.
E-mail addresses: zhangyonghong_1980@163.com (Y. Zhang),
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).the viral genotype.4–6 Despite great improvements in treatment
efﬁcacy, non-virological responders constitute a large part of the
population, and re-treatment of patients is becoming a new
challenge in HCV management due to the lack of optimal therapies
and predictors of sustained virological response (SVR).
The factors that determine the outcome of therapy have been
well documented in naı¨ve patients undergoing combination
therapy, while there are only a few studies focusing on therapy in
previously treated patients. The CC genotype of interleukin (IL)-28B,
HCV genotypes other than type 1, and low viral loads have been
identiﬁed as factors associated with a favorable treatment outcome
in naı¨ve patients on combination therapy with peginterferon alfa
and ribavirin.7–9 However, in published studies, these factors were
rarely able to predict the outcomes of treatment-experienced
patients because the majority were infected with HCV genotype 1,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
S. Zhang et al. / International Journal of Infectious Diseases 33 (2015) 15–2116had high levels of HCV RNA, and carried the CT/TT genotype of the IL-
28B gene.10
Chemokines, a subgroup of small cytokines, direct leukocyte
trafﬁcking and positioning within tissues,11 thus playing an
important role in spontaneous clearance of HCV infection and
long-term resolution with antiviral therapy.12 The levels of
chemokines in peripheral blood have been found to be critical
predictors of responsiveness to antiviral therapy with peginterferon
alfa and ribavirin. For example, levels of monokine induced by
interferon gamma (IFN-g) (MIG), IFN-g-inducible protein 10 (IP-10),
and IFN-inducible T-cell a chemoattractant (I-TAC) could be used to
predict the efﬁcacy of treatment.13–16 In particular, ligands of C-C
chemokine receptor type 5 (CCR5), including chemokines CCL3
(macrophage inﬂammatory protein-1 alpha, MIP-1alpha), CCL4
(MIP-1beta), and CCL5 (regulated upon activation normal T-cell
expressed and secreted, RANTES) play an important role in
predicting antiviral outcome, since they regulate T cell functions
by mediating recruitment, polarization, activation, and differentia-
tion of antiviral type 1 cytokine secreting T helper and cytotoxic T
cells.12,17–19 While most studies have focused on treatment-naı¨ve
patients, data on treatment-experienced patients who have been re-
treated with peginterferon alfa and ribavirin are scarce.
Understanding the difference in chemokine levels between
treatment-naı¨ve and treatment-experienced patients before,
during, and after antiviral therapy is of great importance in the
analysis of effectiveness and the optimization of current treatment
strategies. In order to address this issue, we performed a
prospective longitudinal study to distinguish the peripheral blood
levels of CCR5-associated chemokines MIP-1alpha and MIP-1beta
before therapy and at treatment weeks 4 and 12, between
treatment-naı¨ve and treatment-experienced patients treated with
peginterferon alfa and ribavirin, using the multiplex Bio-Rad 27-
plex assay.
2. Materials and methods
2.1. Patients
This study was approved by the Human Subjects Protection
Committees of Beijing You’an Hospital. Written informed consent
was obtained from all study participants. Eighty HCV-infected
patients (56 treatment-naı¨ve and 24 treatment-experienced who
were null responders to standard interferon and ribavirin), who
were participating in a clinical study designed to assess the efﬁcacyTable 1
Summary of clinical and demographic characteristicsa
Parameter Naı¨ve patients 
Total number 56 
Gender
Male, n (%) 29 (51.8%) 
Female, n (%) 27 (48.2%) 
Age, years 37.82  15.34 
HCV genotype, 1b/2a/others, n 49/7/0 
HCV-RNA load, log10 IU/ml 6.18  1.11 
IL-28B (rs12979860), CC/CT/TT, n 45/11/0 
ALT, IU/l 64.84  53.76 
AST, IU/l 55.88  37.03 
Virological response
SRVRb 14 (27.5%) 
RVR 26 (46.4%) 
EVR 46 (82.1%) 
SVR 45 (80.4%) 
HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
virological response; SVR, sustained virological response; NA, not available; ND, not de
a Results are presented as the mean  standard deviation, or n (%), unless stated other
b Total number of patients enrolled in week 2 = 70, with 10 samples missing.of the treatment regimen (described in detail below) were enrolled
in the study. All patients were negative for HIV and hepatitis B
virus antibodies and underwent combination therapy with
peginterferon alfa 2a (180 mg) and ribavirin (10.6–15 mg/kg/
day) for a total of 48 weeks.20 No cirrhosis or ﬁbrosis was detected
on routine examination of all patients by B ultrasound and
abdominal computed tomography examination. Control subjects
included 11 self-reported healthy volunteers, who were HCV, HBV,
and HIV antibody negative. HCV genotypes were determined using
the Abbott RealTime HCV Genotype II assay kit (Abbott Molecular).
Clinical and demographic characteristics of these patients are
detailed in Table 1. Serial blood samples were collected before
treatment (week 0) and at weeks 4 and 12 after the start of
treatment. Serum was frozen at 20 8C.
2.2. Viral load
HCV RNA was measured in serum using the qualitative Roche
COBAS Amplicor assay (version 2.0; Roche Molecular Systems;
lower limit of detection 50 IU/ml).
2.3. Clinical deﬁnitions
Clinical deﬁnitions are based on viral clearance. Super rapid
virological response (SRVR) was deﬁned as an undetectable serum
HCV RNA level (<50 IU/ml) at week 2 of therapy.21 Rapid
virological response (RVR) was deﬁned as an undetectable serum
HCV RNA level (<50 IU/ml) at week 4 of therapy. Early virological
response (EVR) was deﬁned as an undetectable serum HCV RNA
level at treatment week 12 (cEVR) or an at least 2-log reduction in
serum HCV RNA level from baseline to week 12 of antiviral therapy
(partial EVR). SVR was deﬁned as an undetectable serum HCV RNA
level at the end of the 24-week follow-up period.8
2.4. Measurement of CCR5-associated chemokines
Serum CCR5-associated chemokine levels were measured using
a Human Cytokine 27-plex assay kit (Bio-Rad, Hercules, CA, USA)
with Bio-Plex Manager software version 6.0 in the Bio-Plex
200 System (Bio-Rad). This system allows quantitative measure-
ment of 27 different chemokines, cytokines, growth factors, and
immune mediators, including MIP-1alpha and MIP-1beta, while
consuming 12.5 ml volumes of samples. Chemokines were
evaluated according to the manufacturer’s instructions.Experienced patients Healthy controls
24 11
17 (70.8%) 6 (54.6%)
7 (29.2%) 5 (45.5%)
39.09  16.93 38.12  14.31
21/3/0 NA
6.25  0.98 NA
19/4/1 ND
52.93  47.87 ND
47.31  39.80 ND
2 (10.5%) NA
6 (25.0%) NA
12 (50.0%) NA
12 (50.0%) NA
 SRVR, super rapid virological response; RVR, rapid virological response; EVR, early
tected.
wise.
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Chemokines were compared between patients with and
without SVR using the independent samples t-test. Stepwise
multivariate logistic regression analysis was performed to identify
independent predictors of SVR. Kaplan–Meier analysis was
employed to visualize the difference in dynamics of HCV RNA
between patients with high and low levels of MIP-1beta. Data are
presented as the mean  standard deviation (SD). Differences were
considered signiﬁcant at p < 0.05.
3. Results
3.1. Difference in efﬁcacy during combination therapy between
antiviral-naı¨ve and experienced patients
Overall, 59 of 80 chronic HCV patients (73.75%), including 14 of
24 treatment-experienced and 45 of 56 treatment-naı¨ve patients,
had achieved SVR at the 24-week follow-up. Statistically signiﬁ-
cant differences were found with regard to EVR (82.1% vs. 50.0%;
p = 0.003) and SVR (80.4% vs. 58.3%; p = 0.04) between the
treatment-naı¨ve and treatment-experienced groups. Patients
who were drug-naı¨ve also showed a trend towards a higher SRVR
rate (25.0% vs. 8.3%; p = 0.128) and RVR rate (46.4% vs. 25.0%;
p = 0.073) than patients who were treatment-experienced and re-
treated with combination therapy, although the results showed no
statistical differences (Table 1).
3.2. Baseline features associated with sustained virological response
Clinical and demographic characteristics at baseline signiﬁ-
cantly associated with SVR in all patients were a low viral load
(p = 0.009), history of antiviral therapy (p = 0.04), and pretreat-
ment serum MIP-1beta levels (p = 0.015) by univariate compar-
isons of patients with and without SVR (Table 2). Age, gender, and
serum alanine aminotransferase (ALT) levels were not signiﬁcantly
associated with SVR in all patients. As reported previously for
treatment-experienced patients,10 we found no signiﬁcant associ-
ation between HCV genotype and SVR, although this could also be
due to the low number of non-type 1 patients in our study.
In order to determine which factors were independent
predictors of the ﬁnal treatment outcome, stepwise multivariate
logistic regression analysis of all patients was performed and
indicated that history of antiviral therapy (antiviral-naı¨ve)
(p = 0.028) and pretreatment serum MIP-1beta levels (p = 0.024)
were independent predictors of SVR, whereas baseline HCV viral
load was no longer associated with SVR.Table 2
Patient baseline characteristics and responses to treatmenta
Parameter SVR (n = 57) Without SVR (n = 23) p-Value
Age, years 37.17  15.06 41.00  17.49 0.342
Gender
Male 33 (71.7%) 13 (28.3%) 0.634
Female 26 (76.5%) 8 (23.5%)
HCV genotype
1b 50 (71.4%) 20 (28.6%) 0.278
2a 9 (90%) 1 (10%)
Antiviral therapy
Naı¨ve 45 (80.4%) 11 (19.6%) 0.04
Experienced 12 (50%) 12 (50%)
HCV viral load, log 6.06  1.17 6.58  0.54 0.009
MIP-1a, pg/ml 14.17  11.37 23.64  21.42 0.065
MIP-1b, pg/ml 115.20  54.20 173.05  96.09 0.015
SVR, sustained virological response; HCV, hepatitis C virus; MIP, macrophage
inﬂammatory protein alpha (a) or beta (b).
a Results are presented as the mean  standard deviation, or n (%).3.3. Serum MIP-1 levels and virological response
We then analyzed the impact of baseline MIP-1beta on early viral
kinetics as well as on the ﬁnal treatment outcome in all HCV-infected
patients in the study (Figure 1). Patients were classiﬁed according to
their viral kinetic response during the ﬁrst 2 weeks of therapy.
Signiﬁcantly lower baseline MIP-1 levels were observed in patients
with SRVR (96.54  61.46 pg/ml) compared to those without SRVR
(141.96  75.29 pg/ml, p = 0.031). Similarly, MIP-1beta levels were
signiﬁcantly lower in patients with RVR (107.76  58.22 pg/ml), EVR
(117.18  57.15 pg/ml), and SVR (115.20  54.20 pg/ml), compared
with patients who did not show a response at each corresponding time
point (145.47  76.42, 165.21  93.59, and 173.05  96.09 pg/ml with
p = 0.02, 0.033, and 0.015, respectively).
3.4. Ideal threshold for MIP-1beta level to predict sustained virological
response
To identify a suitable threshold for baseline serum MIP-1beta
level, a receiver operating characteristic (ROC) curve for predicting
SVR was calculated and showed an area under the curve (AUC) of
0.67 (95% conﬁdence interval 0.5413–0.7976). The calculated
threshold for predicting SVR was 95.23 pg/ml, with positive and
negative predictive values of 100.0% and 27.27%, respectively
(Figure 2).
MIP-1beta levels below this threshold were highly predictive of
the achievement of SVR in both treatment-naı¨ve and treatment-
experienced patients (100% and 86% positive predictive value,
respectively; Figure 3a–c). Levels above the threshold were
reasonably predictive of failure to achieve SVR in treatment-
experienced patients (65% negative predictive value; Figure 3c).
Furthermore, a rapid reduction in HCV RNA during the ﬁrst
12 weeks of therapy was observed in patients with a baseline MIP-
1beta <95.23 pg/ml, compared with a slow decline in patients with
baseline MIP-1beta 95.23 pg/ml (p = 0.0004). This correlation
was found not only for treatment-naı¨ve patients (p = 0.0142), but
also for treatment-experienced patients who were re-treated with
combination therapy (p = 0.015) (Figure 3).
3.5. Dynamics of MIP-1beta during combination therapy between
antiviral-naı¨ve and experienced patients
The dynamics of MIP-1 levels before and during treatment in
treatment-naı¨ve and experienced patients are presented in
Figure 4. MIP-1beta levels at baseline were signiﬁcantly lower
in treatment-naı¨ve patients who achieved an SVR than in patients
without SVR (p = 0.014). A similar difference was observed in
treatment-experienced patients (p = 0.04). After 4 weeks of
therapy, MIP-1 levels were reduced by 30 pg/ml in most patients,
whether treatment-naı¨ve or treatment-experienced. Twelve
weeks after combination therapy, MIP-1beta levels in all patients
with SVR were signiﬁcantly lower than in patients without SVR,
and approached those in healthy controls.
3.6. Correlation between MIP-1 and transaminases before antiviral
therapy
We measured liver transaminase levels as indicators of hepatic
inﬂammation. A clear positive correlation between pretreatment
MIP-1beta and the level of ALT (p = 0.01) was found in the study
population, as well as a similar trend between MIP-1beta and
aspartate aminotransferase (AST, p = 0.0086; Figure 5a and
b). Using the ideal predictive threshold value we determined for
MIP-1beta, transaminase levels were compared in patients with
low (<95.23 pg/ml) and high (95.23 pg/ml) baseline chemokine.
The level of ALT in patients with low MIP-1beta was found to be
Figure 1. Low pretreatment MIP-1 levels are associated with early and sustained virological responses. Pretreatment MIP-1beta levels of 80 chronic HCV patients during
combination therapy with peginterferon alfa and ribavirin are shown. Patients are classiﬁed according to their viral kinetic responses after 2 weeks (SRVR, 1a), 4 weeks (RVR,
1b), 12 weeks (EVR, 1c), and at the end of the 24-week follow-up period (SVR, 1d) into those with and without each virological response (MIP, macrophage inﬂammatory
protein; HCV, hepatitis C virus; SRVR, super rapid virological response; RVR, rapid virological response; EVR, early virological response; SVR, sustained virological response).
Figure 2. Identiﬁcation of the ideal threshold of pretreatment macrophage
inﬂammatory protein 1beta (MIP-1beta) to predict sustained virological
response (SVR). A receiver operating characteristic (ROC) curve was employed to
identify a suitable threshold for serum pretreatment MIP-1beta levels in the
prediction of SVR. The resulting threshold for predicting SVR was 95.23 pg/ml, with
positive and negative predictive values of 100.0% and 27.27%, respectively.
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MIP-1beta (71.36  8.05 IU/l, p = 0.001), and the level of AST in low
MIP-1beta patients (38.34  3.44 IU/l) was also lower than that in
high MIP-1beta patients (60.52  5.81 IU/l, p = 0.0016) (Figure 5c and
d).
4. Discussion
The re-treatment of patients who fail initial antiviral therapy is
becoming a new challenge in HCV management in the wake of the
increasing numbers of non-virological responders. It has been
reported that current recommended combination therapy withpeginterferon alfa and ribavirin can lead to long-term resolution of
HCV infection in 22–40% of treatment-experienced chronic HCV-
infected individuals who receive a second round of antiviral
therapy. The low level of SVR in treatment-experienced patients
has increased the urgency of optimizing current treatment
strategies and of identifying parameters to effectively predict
the outcome of treatment.
Although host genetics, viral subtypes, and high viral loads are
parameters that can be used to predict the outcome of antiviral
therapy in treatment-naı¨ve patients,7–9 these factors have only a
small role in the prediction of virological response in treatment-
experienced patients who receive second round antiviral thera-
py.10 Host immune responses might also play a key role in HCV
clearance during therapy,22,23 but the immune mediators associ-
ated with favorable viral response in treatment-experienced
patients have not been well characterized.
Chemokines constitute a large family of small proteins
consisting of four main subfamilies – CXC, CC, C, CX3C – mediating
their effects on a family of seven-transmembrane domain
G-protein coupled receptors. The CC chemokines including
chemokines CCL3 (MIP-1alpha), CCL4 (MIP-1beta), and CCL5
(RANTES) are expressed by the portal vessel endothelium and
recruit macrophages and lymphocytes into the liver.24,25
Most studies have shown increased intrahepatic and/or blood
levels, as well as increased expression of the CXC and CC families of
chemokines in chronic HCV infection.18,25 As for the relationship
between the CC chemokines and the liver necroinﬂammatory
activity or the ﬁbrosis grade, there are conﬂicting results
concerning this topic. In one study, serum MIP-3a and ALT
correlated signiﬁcantly;26 in another study, intrahepatic RANTES
expression correlated well with the histological activity.27 In
contrast, in another study, the expression of RANTES or MIP-1beta
in the liver did not correlate with necroinﬂammation activity
scores;28 in an additional study, the serum levels of CC chemokines
Figure 3. The pretreatment level of macrophage inﬂammatory protein 1beta (MIP-1beta) is strongly predictive of the virological response and HCV clearance in treatment-
experienced patients. A Chi-square test was employed to determine the difference in achieving SVR after recommended antiviral therapy between patients with high and low
levels of MIP-1beta in the total study population (3a), treatment-naı¨ve patients (3b), and treatment-experienced patients (3c). Positive and negative predictive values (PPV
and NPV, respectively) are indicated. Kaplan–Meier curves of cumulative HCV RNA positive (deﬁned as serum viral load >50 IU/ml) during 48 weeks of treatment and at
24 week post-treatment follow-up. Patients are grouped as low level MIP-1beta (<95.23 pg/ml) and high level MIP-1beta (95.23 pg/ml). HCV clearance is presented in the
total study population (3d), treatment-naı¨ve patients (3e), and treatment-experienced patients (3f).
Figure 4. Macrophage inﬂammatory protein 1b (MIP-1b) levels during combination therapy correlate with sustained virological response (SVR) in treatment-naı¨ve and
experienced patients. MIP-1beta was detected at baseline (week 0), week 4, and week 12 during combined therapy. Columns represent the means with standard deviations at
each time point. Signiﬁcant differences (p < 0.05) between patients with and without SVR in the treatment-naı¨ve and experienced groups are highlighted with an asterisk (*).
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or the ﬁbrosis grade.18
The most signiﬁcant ﬁnding of the present study is the
association of serum CCL4 (MIP-1beta) levels with early and
sustained virological responses to combination therapy with
peginterferon alfa and ribavirin in treatment-naı¨ve and experi-
enced patients with chronic HCV infection. We found that
pretreatment MIP-1beta concentrations lower than 95.23 pg/ml
had a positive predictive value of 96% in all treated patients, and
86% in treatment-experienced patients. Given that a high
proportion of treatment-experienced patients with pretreatment
MIP-1beta levels below this threshold achieved SVR, this
parameter could be a valuable predictor of viral responses and a
key marker to evaluate the outcomes of antiviral therapy, help
optimize treatment strategies, or guide personalized therapy,
particularly in treatment-experienced patients.
Of note, a signiﬁcant difference in serum MIP-1beta before and
during therapy between patients with and without SVR suggests
that immunological status might play an important role in theresolution of chronic HCV infection. Patients with a low level of
MIP-1beta seem more likely to achieve SVR than those with a high
level. The role of immunological status in antiviral therapy was
also demonstrated in a recent study documenting a correlation
between dominant Th1-polar cytokine proﬁles and favorable
combination therapy outcome in treatment-experienced
patients.23 In addition, the biological function of MIP-1beta, from
stimulation of the Th1 response and regulation of T cell functions
to aggravation of inﬂammation,11,19,24 supports a role for MIP-
1beta in the control of chronic HCV infection.
One of the most intriguing observations in our present study
was that a high level of pretreatment MIP-1beta was associated
with elevation of transaminases, while a low level before and
during antiviral therapy was associated with a favorable outcome.
During chronic HCV infection, persistent HCV in the liver may
induce continual chemokine production,16,29 which may in turn
induce chemokine receptor down-regulation on T cells by
endocytosis,30 or attract non-speciﬁc mononuclear cells to the
liver,19 resulting in chronic liver damage. For those patients with a
Figure 5. Correlation between pretreatment macrophage inﬂammatory protein 1b (MIP-1beta) level and liver inﬂammation. A clear positive correlation between
pretreatment MIP-1beta and the level of alanine aminotransferase (ALT) was identiﬁed (5a), and the same trend was identiﬁed between MIP-1beta and aspartate
aminotransferase (AST) (5b). 5c and 5d display the differences in status of liver inﬂammation between patients with low levels of MIP-1beta (<95.23 pg/ml) and high levels of
MIP-1beta (95.23 pg/ml).
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tory inﬁltration of the liver would not be induced, which might
favor successful antiviral therapy.
The clear association of serum MIP-1 levels with early and
sustained virological responses to combination therapy, as well as
the positive correlation between pretreatment MIP-1beta and the
elevation of transaminases, further conﬁrms the critical role of
immunological status before antiviral therapy in the prediction of
the outcome of antiviral therapy, especially for those treatment-
experienced patients undergoing second round antiviral therapy.
This is the ﬁrst report supporting a low level of MIP-1beta as a
signature of a favorable viral response in treatment-experienced
patients after second round therapy. The results obtained here
support the development of further studies to clarify the role of the
host immune response in the success of re-treatment in treatment-
experienced patients.
Our analysis focused solely on circulating ligands of CCR5.
Further studies on the interaction between chemokines and the
CCR5 receptor, as well as the association between immune
responses in the liver and virus control during combination
therapy in treatment-experienced patients, will help to delineate
new immunotherapeutic strategies and improve current treat-
ment regimens.31
Nowadays, the treatment of chronic HCV infection has already
moved into the era of direct-acting antiviral (DAA) agents.
Presently, two DAA agents, boceprevir (BOC) and telaprevir
(TVR), have been approved by the US Food and Drug Administra-
tion (FDA). Both are potent inhibitors of HCV genotype 1 replication
and markedly improve SVR rates in treatment-naı¨ve and
treatment-experienced patients. The practice guidelines of the
American Association for the Study of Liver Disease published in
2011 suggest that for treatment-experienced null responders to acourse of standard interferon alfa, re-treatment with telaprevir
together with peginterferon alfa and weight-based ribavirin may
be considered.32
In the most recently published European Association for the
Study of the Liver (EASL) recommendations for the treatment of
HCV, it was reported that three new DAAs would be licensed in the
European Union in the ﬁrst half of 2014 for use as part of
combination therapies for HCV infection. Sofosbuvir, a nucleotide
analogue inhibitor of HCV RNA-dependent RNA polymerase, was
approved in January 2014. Simeprevir, a second-wave, ﬁrst-
generation NS3/4A protease inhibitor was due for approval in
May 2014. Daclatasvir, an NS5A inhibitor, was due to be approved
in August or September 2014. In 2014, both treatment-naı¨ve and
experienced patients with compensated disease will beneﬁt from a
broad choice of drug combinations.33 However, neither DAA is
presently approved for use in China.
In conclusion, our study found that serum MIP-1beta is an
independent predictor of early and sustained virological response
in chronic HCV-infected patients, and most importantly, that a low
pretreatment level of MIP-1beta can reliably predict a favorable
outcome of second round combination therapy in treatment-
experienced chronic HCV infections. As high level MIP-1beta may
play a role in the mechanism of migration impairment and
inﬂammatory inﬁltration of the liver during the chronic phase,
recovery of T cell migration or blocking the inﬁltration of non-
speciﬁc T cells may constitute new strategies to improve the
treatment outcome of these difﬁcult-to-cure patients.
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